Canidryl 50 mg Tablets for dogs

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Osta kohe

Toote omadused Toote omadused (SPC)
12-06-2017
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
04-07-2023
DSU DSU (DSU)
25-10-2023

Toimeaine:

Carprofen

Saadav alates:

Chanelle Pharmaceuticals Manufacturing Limited

ATC kood:

QM01AE91

INN (Rahvusvaheline Nimetus):

Carprofen

Annus:

50 mg/tablet

Ravimvorm:

Tablet

Retsepti tüüp:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutiline rühm:

Dogs

Terapeutiline ala:

carprofen

Näidustused:

N.S.A.I.D.

Volitamisolek:

Authorised

Loa andmise kuupäev:

2006-03-03

Toote omadused

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Canidryl 50 mg Tablets for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENT
Carprofen 50.0 mg/tablet
EXCIPIENTS
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
A plain round flat bevelled edge white to off white tablet with a
breakline on one side. The tablets can be divided into
equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and degenerative joint disease. As a follow
up to parenteral analgesia in the management of post-operative pain.
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pups less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any
of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastro-intestinal
ulceration or bleeding, or where there is evidence of a blood
dyscrasia.
Refer to section 4.7.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_3_
_0_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_0_
_8_
_2_
_6_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in aged dogs, may involve additional risk. If such a use cannot be
avoided, dogs may require care
                                
                                Lugege kogu dokumenti
                                
                            

Otsige selle tootega seotud teateid